Expression of Apoptosis Related and Proliferative Proteins in Malignant Lympho-Proliferative Disorders

Document Type: Original Research

Authors

1 Dept. of Pathology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India

2 National Institute of Pathology, Indian Council Of Medical Research, Safdarjung Hospital Complex, New Delhi India

3 Dept. of Haematology Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

4 Dept. of Radiotherapy, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

Abstract

Background & objective: The current study aimed to perform an immunohistochemical analysis of patterns of apoptotic and cell proliferative related protein expression in different histological grades and immune phenotypes of malignant lymphomas and other lymphoproliferative disorders
Methods:This observational study was carried on 60lymph node biopsies of lymphoproliferative disorders. The biopsies were analyzed histologically and immunohistochemically.
Results:A total of 60 lymph node biopsies were included in the study, of which 81.6% were of malignant lympho-proliferative lesions. The majority of the biopsies were B-cell (66%) and were grouped in the intermediate grade. Bax and BCL-2 protein expression was presented by percentage of immune positive neoplastic cells per 10fields and graded on a scale of 1 to4. A Bcl-2, Bax Protein Ratio (BBPR) was determined for each case by dividing the estimated Bcl-2 protein (percentage of Bcl-2 positive cells x Bcl-2 staining intensity) by the estimated Bax protein (percentage of Bax positive cells x Bax immunostaining intensity). The mean BBPR was found to be significantly higher in indolent lymphomas (2.64 ± 1.3) as compared to aggressive lymphomas (0.47 ± 0.9) (P<0.01). The expression of P53 and PCNA in 35 biopsies of Non Hodgkin Lymphomas (NHL) was found to increase from low to high grade tumors.
Conclusions: A significant correlation was found between BBPR and predicted biological behavior of indolent and aggressive lymphomas. This indicates the important role of Bcl-2 and Bax in biological behavior of lymphomas. Furthermore, P53 and PCNA expression were found to increase from low to high-grade tumors suggesting their prognostic value in NHL.

Keywords


1. Canioni D, Jabado N, MacIntyre E, Patey N, Emile JF, Brousse N. Lymphoproliferative disorders in children with primary immunodeficiency; immunological status may be more predictive of the outcome than other criteria. Histopathol2001;38:146-159.

2. Rizzo K, NassiriM.Diagnostic Workup of Small B Cell Lymphomas: A Laboratory Perspective Lymphoma
Volume 2012:Article ID 346084,doi:10.1155/2012/346084

3. Dorfman RF, Gelb AB, Hendrickson MR. Composite lymphoma Am J Pathol 1992; 40: 959-76

4. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. –Its significance in cancer and cancer therapy. Cancer 1994; 73:2013-26.

5. Anderson MA, Huang D,RobertsA. Targeting BCL2 for the Treatment of Lymphoid Malignancies. SeminHematol 2014; 51:219–227.

6. Gaulard P, Agay MF, M. Peuchmaur, N Brousse, C. Gisselbrecht, P. Solal-Celignyet al. Bcl-2 expression in diffuse aggressive lymphoma. Am J Pathol 1992; 140:1089-95.

7. Wheaton S, Netser J, Guinee D, Rahn M, Perkins S.BCL-2 and Bax protein expression and indolent versus aggressive B-cell non- Hodgkin’s lymphomas. Human Pathology 1998;29: 820-25.

8. Korsemeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. BCL-2 / Bax: a rheostat that regulates an antioxidant pathway and cell death. Semin Cancer Biol. 1993; 4: 327-32.

9. Sahu SK, Choudhuri T. Lack of Association between Bax Promoter (-248G>A) Single Nucleotide Polymorphism and Susceptibility towards Cancer: Evidence from a Meta-Analysis. PLoS ONE 2013; 8(10): e77534. doi:10.1371/journal.pone.0077534

10. Soiniy Y, Paakko P.  Apoptosis and ex-pression of caspases 3, 6 and 8 in malignant non- Hodkins lymphomas. APMIS. 1999;107: 1043- 50.

11. Oltavi ZN, Millman CL & Korsmeyer SJ.Bcl-2 heterodimers in vivo with a conserved homologue, Bax, that accelerates programmed cell death. 1993.Cell;74 :609–619.

12. M R. Hussein, TM Al-SabaeMarcelle, N. Georgis. Analysis of the Bcl-2 and p53 Protein Expression
in the LymphoproliferativeLesions in the Upper Egypt. Cancer Biology & Therapy 2005;4: 324-28.

13. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC . Prognostic significance of Bax protein expression in diffuse agressive non-Hodkin’ s lymphoma. Blood. 1997; 90: 3173-8

14. Winter JNN, Andersen J, Reed JC,KrajewskiS,Variakojis D, Bauer KDet.al. Bcl-2 expression correlates with lower proliferative activity in the intermediate-and high grade non- Hodkins lymphomas: an Eastern Cooperative Oncology group and southwest Oncology group cooperative laboratory study. Blood. 1998; 91: 1391-8.

15. Flora Tzifi, Christina Economopoulou, DimitriosGourgiotis, AlexandrosArdavanis,SotiriosPapageorgiou,AndreasScorilas. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Advances in Hematology
Volume 2012, Article ID 524308, 15 pages

16. El-Esawy, B. H. The Immunohistochemistry Based Evaluation of Bcl-2 in B Non Hodgkin lymphoma & Its Prognostic Significance. Life Sci J 2013;10: 3290-3295

17. NY Samuel, Matthew S. Davids. Selective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Clinical Advances in Hematology & Oncology 2014;12: 224-29.

18. CD Goia, AR Lupu, C Bleotu, C Antipa, Lvelt, E Popa, G Constantinescu,  Correlation Between Pro- And Anti-Apoptotic Gene Expression And Telomerase Activity In B- Cell Lymphomas. Proc. Rom. Acad2008;3:169–174

19. Charalambous GK, Gomatos IP, Konstadoulakis MM, MessarisEG, Manouras AJ, 
Apostolou AE et.al. Protein expression of bax, bcl-2, and p53 in patients with nonHodgkin’s gastric lymphoma: Prognostic significance. World J Surg 2000; 24:608-14.

20. Burra U, Shanthi P, Krishnan KB, Madhavan M. P 53 and PCNA in Non Hodgkin’s lymphoma—an immunohistochemical evaluation. Indian J PatholMicrobiol 2000; 43:61-4.

21. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-5.

22. Korkolopoulou P, Oates J, Kittas C, Crocker J. P-53, c-myc, P-62 and proliferating cell nuclear antigen (PCNA) expression in no Hodgkin’s lymphomas. J Clin Pathol.1994; 47: 9-14.

23. Rabenhorst SH, Burini RC, Schmitt FC. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology. 1996; 28:12-6.

24. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Ioannis A.et al: Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immuno- globulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-50.

25. Garcia JF, Camacho FI, MorenteM,Fraga M, Montalban C, Alvaro T.et.al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 2003;101:681-689

26. SJ. Sup, C A. Aleman ̃y, B Pohlman, P Elson, S Malhi, SThakkar. Expression of bcl-2 in Classical Hodgkin’s Lymphoma: An Independent Predictor of Poor Outcome. J ClinOncol 2005;23:3773-79.

27. EDerenzin,AYounes. Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. Genome Medicine 2011, 3:26

28. Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F, Rigal-Huguet F.et.al. Frequent expression of cell death inducing gene Bax in Reed Sternberg cells of Hodgkin’s disease. Blood 1996; 87: 2470-5.

29. KanavarosP, Stefanaki K, Viachonikolis J. Expression of P-53, P-21 / Waf1, BCL-2, Bax, Rb and Ki67 proteins in Hodgkin’s lymphomas. Histopathol 2000;15: 445-53.

30. Smolewski P, Niewiadomska H, Blonski JZ, Robak T, Krykowski E.et.al. Expression of proliferating cell nuclear antigen (PCNA) and P-53, BCL-2 or C-erb B -2 proteins on Reed Sternberg cells: prognostic significance in Hodgkin’s disease. Neoplasma.1998; 45: 140-7.